Skip to main content

It's time to put on the pressure

You can not discriminate against me because I might develop a given health problem. You can not use my genes against me. It isn't right, but apparently there are a few senators having a tough time with the concept. Here's the latest GINA (Genetic Non-Discrimination Act) update.


The House is working this weekend to get an omnibus bill together for Monday. Your calls have helped – but efforts to block it have been stepped up with another hold on the bill: Senator McConnellH.R. 493, the Genetic Information Nondiscrimination Act (GINA) Summary: The Genetic Information Nondiscrimination Act (GINA) would prohibit insurers and employers from discriminating based solely on a person’s genetic information. Title I protects an individual from insurance discrimination. Title I applies to employer-sponsored group health plans, health insurance issuers in the group and individual markets, Medigap insurance, and state and local non-federal governmental plans.Title II prohibits the use of genetic information in employment decisions, such as hiring, firing, job assignments, and promotions. This prohibition extends to employers, unions, employment agencies, and labor-management training programs.Status:
Passed in the House of Representatives on April 25, 2007 by a vote of 420-3.
The bill has 224 cosponsors, including 95 Republicans.
Passed in the Senate in the 108th and 109th Congresses by votes of 95-0 and 98-0 respectively.
McConnell voted for GINA both times.
Coburn voted for GINA in the 109th. He was not in the Senate in the 108th. Coburn now has a hold on the bill, so we cannot get a vote in the Senate.

The President has issued 3 Statement of Administration Policies in support of the bill.
The bill also enjoys the support of 200+ organizations.
ACTION: Call Senator McConnell and tell him you support putting GINA in the Omnibus: Tel: (202) 224-2541 Fax: (202) 224-2499 Email:
http://mcconnell.senate.gov/contact_form.cfm <http://mcconnell.senate.gov/contact_form.cfm>

Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria